Search
Thenalidine
go.drugbank.com/drugs/DB04826ApprovedWithdrawnWithdrawn from the Canadian, US, and UK markets in 1963 due to concerns involving neutropenia.
Synonyms: 1-Methyl-4-amino-N-phenyl-N-(2-thenyl)piperidine, 1-Methyl-4-N-2-thenylanilinopiperidineOditrasertib
go.drugbank.com/drugs/DB21526InvestigationalOditrasertib is under investigation in clinical trial NCT05630547 (A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis … Oditrasertib is a small molecule drug. The usage of the INN stem '-sertib' in the name indicates that Oditrasertib is a serine/threonine kinase inhibitor.
Sirpiglenastat
go.drugbank.com/drugs/DB17536InvestigationalIt is under investigation in clinical trial NCT04471415 (Study to Investigate DRP-104 in Adults With Advanced Solid Tumors). … Sirpiglenastat, also known as DRP-104, is a prodrug of [6-diazo-5-oxo-L-norleucine] (DON), which is a broad-acting glutamine antagonist.
Synonyms: L-norleucine, n-acetyl-l-tryptophyl-6-diazo-5-oxo-, 1-methylethyl ester, Propan-2-yl (2s)-2-((n-acetyl-l-tryptophyl)amino)-6-diazo-5-oxohexanoateOpnurasib
go.drugbank.com/drugs/DB21583InvestigationalOpnurasib is under investigation in clinical trial NCT05132075 (Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer … Opnurasib is a small molecule drug. The usage of the INN stem '-rasib' in the name indicates that Opnurasib is a Ras protein inhibitor.
Bosakitug
go.drugbank.com/drugs/DB19101InvestigationalBosakitug (BSI-045B) is under investigation in clinical trial NCT05932654 (POC Study to Evaluate BSI-045B Monotherapy and BSI-045B Add-on Therapy With Dupilumab in Atopic Dermatitis).
MGN-4893
go.drugbank.com/drugs/DB17338ExperimentalMGN-4893 is an inhibitor of microRNA-451. In February 2011, it was granted FDA orphan designation for the treatment of polycythemia vera.[L47356]
ONT-093
go.drugbank.com/drugs/DB14069ExperimentalIn pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics. … ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp).
Anfibatide
go.drugbank.com/drugs/DB15094InvestigationalAnfibatide is under investigation in clinical trial NCT01585259 (Anfibatide Phase Ib-IIa Clinical Trial).
Ochromycinone
go.drugbank.com/drugs/DB15644InvestigationalOchromycinone is under investigation in clinical trial NCT01047943 (STA-21 Topical Efficacy on Psoriasis).
Carlumab
go.drugbank.com/drugs/DB12718ApprovedWithdrawnCarlumab has been used in trials studying the treatment of Cancer and Prostate Cancer.